Biovation Signs Research Agreement With Centocor
Biovation Limited of Aberdeen, UK, a Merck KGaA group company, today announced the signing of a research agreement with Centocor Inc., under which Biovation will apply its proprietary DeImmunisation technology to novel therapeutic proteins designed by Centocor. Biovation will receive research revenues and, in the event Centocor selects proteins for further development, could earn license fees, milestone payments and royalties on future product sales.
Dr. Frank Carr, President and Chief Executive Officer of Biovation, commented, "We are delighted to be working with Centocor, a pioneer in the immunotherapy of human diseases. This is an excellent opportunity for us to extend the application of DeImmunisation and produce further clinical products."
DeImmunisation represents an entirely different approach to reducing immunogenicity. The technology addresses a major driver of immunogenicity in therapeutic antibodies and proteins, namely T cell epitopes. The DeImmunisation technology involves the identification and removal of T cell epitopes from the molecule. Since potentially immunogenic regions of the molecule are removed by single amino acid substitutions, immunogenicity can be eliminated while retaining the properties of the starting molecule.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous